ZELLTEK S.A. is a company owned by the AMEGA Biotech group which opened its production plant at PTLC in 2009. It was the first biotechnology company to be incubated in an Argentine university environment closely linked to the technology and science sector.
It has developed a complete multi-step procedure for the production of recombinant human erythropoietin (rhEPO) as an active ingredient, from the fermentation of genetically modified cells in bioreactors to the production of the pure bio-therapeutic protein, ready to use to formulate the final product.
At present, the company’s premises cover an area of de 10,000 m2 and its production capacity has increased significantly thus granting it access to different markets worldwide.
